The Company
Harrow (NASDAQ: HROW) is an ophthalmic-focused pharmaceutical company that develops, acquires and commercializes prescription and specialty ophthalmic products and provides large-scale compounding services through its ImprimisRx subsidiary. It sells branded, FDA-approved ophthalmic medicines (e.g., VEVYE®, IHEEZO®, TRIESENCE®) and continues to operate ImprimisRx, a national ophthalmic compounding outsourcing facility. harrow.com+1
Financials (key recent figures & trend)
- FY-2024 revenue: $199.6M (up ~53% vs FY-2023).
- Q4-2024 revenue: $66.8M (up ~84% YoY); Q4-2024 GAAP net income was $6.8M while FY-2024 GAAP net was a loss (company reported GAAP FY net loss in disclosure). The company reported strong margin profile and improving profitability metrics in late-2024 / early-2025 commentary and has given aggressive 2025 revenue targets/guidance. Yahoo Finance+1
- Recent run-rate / guidance: Management commentary and investor letters indicated targets north of ~$280M revenue for 2025 (management guidance / commentary). Harrow’s reported revenue growth in early-2025 continued the trend of branded product growth outpacing compounding. Business Wire+1
Bottom line: Harrow moved in 2023–2024 from being compounding-centric (ImprimisRx) toward a higher-margin branded specialty ophthalmic product company; revenue has grown rapidly and management is projecting further meaningful growth as branded sales scale. SEC+1
TAM / CAGR (market opportunity)
- Primary market (ophthalmic drugs / ophthalmology therapeutics): estimates vary by source, but recent market research places the global ophthalmic drugs market in the ~$38–41B range (2024/2025) with projected CAGR ≈ 6–8.5% over the next 5 years depending on the report and segment assumptions. Grand View Research+1
- Relevant sub-market (dry eye disease): the dry-eye therapeutics market (a core focus because of VEVYE®) is typically sized in the multi-billion USD range (examples: ~$6B+ in near-term vintage estimates) with mid-single-digit CAGRs in some reports; dry-eye remains an important, growing prescription segment due to aging populations and increased diagnosis. Mordor Intelligence+1
Products (table) — products / services & revenue split (calendar/FY-2024)
How the split below was estimated: Harrow’s FY-2024 total revenue is public; the company has published ImprimisRx historical revenue amounts and commentary showing branded product revenues exceeded ImprimisRx in 2024. The category percentages below are calculated from those published figures and are presented as company-level category splits (approximate). Yahoo Finance+1
| Product / Revenue Category | Examples / Notes | FY-2024 revenue (approx.) | % of FY-2024 revenue (approx.) |
|---|---|---|---|
| Branded Specialty Ophthalmic Products (SBP) | VEVYE® (dry eye), IHEEZO® (ocular anesthesia), TRIESENCE® (retina corticosteroid), acquired Santen front-of-eye portfolio, etc. | ~$116.1M (calculated) | ~58% |
| ImprimisRx (compounded products / pharmacy services) | Large-scale ophthalmic compounding (sterile/outsource facility) and other compounded/sterile products | ~$83.5M (reported ImprimisRx FY-2024 revenue) | ~42% |
| Total Harrow FY-2024 | — | $199.6M (reported) | 100% |
Notes/assumptions: the ImprimisRx figure above is taken from company reporting/analyst summaries for 2024; the branded category is the remainder (total minus ImprimisRx). Harrow’s disclosure emphasized that branded product revenue meaningfully exceeded ImprimisRx for the first time in 2024 and that branded momentum (notably VEVYE) is expected to accelerate. Presenting category splits at a more granular (individual product % of revenue) level would require company disclosure by product which the company does not fully break out publicly in all filings — so the table uses the reported category numbers and transparent math. Seeking Alpha+1
Business Model
Harrow operates a hybrid model: (1) commercialize and scale FDA-approved branded ophthalmic medicines (commercial sales force, specialty pharmacy channels, distributor/PBM relationships), (2) manufacture and distribute compounded ophthalmic products through ImprimisRx (outsourcing facility / compounding pharma services), and (3) bolt-on acquisitions / in-license older or niche ophthalmic assets and relaunch them (e.g., TRIESENCE relaunch, acquired Santen portfolio). This mix gives Harrow near-term cash from compounding while branded products aim to deliver higher margin, recurring prescription revenue as coverage/brochure penetration improves. harrowinc.gcs-web.com+1
Customers
- Primary customers: eye care professionals (ophthalmologists, optometrists), specialty pharmacies and institutional purchasers, surgical centers (for retina/cataract injectable supplies), and third-party distributors / PBMs that manage branded prescription coverage. ImprimisRx also supplies physician offices and surgical centers that rely on compounded sterile ophthalmic products. harrow.com+1
Competitors (top 3 — direct competing products)
I list three large, obvious competitors whose products compete directly with Harrow’s key franchises (especially dry-eye and front-of-eye ophthalmic products):
- AbbVie (Allergan) — RESTASIS® (cyclosporine ophthalmic emulsion) is a long-standing prescription dry-eye product; AbbVie/Allergan’s scale, payer programs and historical leadership in prescription dry-eye make it a primary competitor for VEVYE’s market. restasis.com
- Bausch + Lomb — XIIDRA® (lifitegrast) (acquired from Novartis) is a leading prescription dry-eye therapy and competes directly in the inflammation-targeting DED segment; Bausch + Lomb’s commercial footprint is a direct competitive force. Bausch Health Investor Relations+1
- Large ophthalmic incumbents & compounding peers (Alcon / local compounding pharmacies) — for surgical/retina products and sterile injectable supplies, Alcon, Bausch + Lomb (broad portfolio), and regional compounding pharmacies / specialty pharmacies represent competition to TRIESENCE, IHEEZO and ImprimisRx. (Alcon, Bausch + Lomb and other majors supply many front-of-eye and retina products and controls distributor/surgeon relationships.) Investing.com+1
Note: competition in ophthalmology is split between branded Rx rivals (large pharma with well-established products and payer programs) and compounding / specialty pharmacy rivals (smaller, regional players and national compounding outfits). Harrow competes in both worlds. Seeking Alpha+1
Founding History
- Founded / origin: Harrow traces its roots to the Imprimis business and the company publicly positions its founding in 2011 (Imprimis era) and underwent a corporate rebrand from Imprimis Pharmaceuticals to Harrow Health (later shortened to Harrow, Inc.) around late-2018 / 2019 to reflect the broader strategic shift from compounding-only to a branded ophthalmic platform. CEO Mark L. Baum has been a central figure in that transition. Over the 2010s Harrow built the ImprimisRx compounding business and later expanded by acquiring or relaunching branded ophthalmic products (VEVYE, TRIESENCE relaunch, Santen portfolio elements etc.).
Invest Alpha 